Gilead, Cipla Ink Deal To End HIV Drug Buyers' Antitrust Suit <https://www.law360.com/competition/articles/1808926?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-03-04&read_main=1&nlsidx=0&nlaidx=7> By Gina Kim Gilead Sciences Inc. and generics maker Cipla told a California federal judge Friday they've reached a settlement ending a proposed class action filed by a public employees' health insurance fund over an alleged anti-competitive patent deal to delay the launch of a generic version of the HIV drug Truvada. 1 document attached | Read full article » <https://www.law360.com/competition/articles/1808926?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-03-04&read_more=1&nlsidx=0&nlaidx=7> | Save to favorites » <https://www.law360.com/competition/articles/1808926?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-03-04&read_later=1&nlsidx=0&nlaidx=7>